1. Home
  2. VRRM vs ZYME Comparison

VRRM vs ZYME Comparison

Compare VRRM & ZYME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Verra Mobility Corporation

VRRM

Verra Mobility Corporation

HOLD

Current Price

$4.67

Market Cap

2.0B

ML Signal

HOLD

Logo Zymeworks Inc.

ZYME

Zymeworks Inc.

HOLD

Current Price

$22.88

Market Cap

1.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VRRM
ZYME
Founded
1987
2003
Country
United States
United States
Employees
N/A
264
Industry
Transportation Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.0B
1.7B
IPO Year
2016
2022

Fundamental Metrics

Financial Performance
Metric
VRRM
ZYME
Price
$4.67
$22.88
Analyst Decision
Buy
Strong Buy
Analyst Count
5
11
Target Price
$25.90
$38.90
AVG Volume (30 Days)
10.7M
610.6K
Earning Date
05-06-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
347.37
33.33
EPS
0.17
N/A
Revenue
$132,969,000.00
$105,965,000.00
Revenue This Year
$6.84
$183.10
Revenue Next Year
$6.88
N/A
P/E Ratio
$26.47
N/A
Revenue Growth
14.61
38.87
52 Week Low
$3.40
$11.86
52 Week High
$25.83
$29.75

Technical Indicators

Market Signals
Indicator
VRRM
ZYME
Relative Strength Index (RSI) 23.47 36.59
Support Level $3.40 $22.28
Resistance Level $25.10 $23.66
Average True Range (ATR) 0.53 0.92
MACD 0.02 -0.15
Stochastic Oscillator 12.71 17.07

Price Performance

Historical Comparison
VRRM
ZYME

About VRRM Verra Mobility Corporation

Verra Mobility Corp is a provider of smart mobility technology solutions, principally operating throughout the United States, Australia, Europe, and Canada. The company develops and uses technology and data intelligence to help make transportation safer and easier. It operates in three reportable segments: Commercial Services, Government Solutions, and Parking Solutions. Maximum revenue is generated from the Commercial Services segment, which offers toll and violation management solutions and title and registration services for commercial fleet customers, including RACs and FMCs in North America. In Europe, it provides tolling and violations processing services.

About ZYME Zymeworks Inc.

Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. It is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.

Share on Social Networks: